Using a randomized clinical trial design, the authors compared the ability of etomidate to provide total intravenous (IV) anesthesia with propofol.1 Propofol is the most common IV anesthesia medication used for general anesthesia in combination with analgesia and neuromuscular blockade. But propofol is far from perfect with an adverse effect profile having significant effect on cardiovascular parameters, including reduced blood pressure and elevated heart rate. In contrast, etomidate maintains cardiovascular stability with administration. Yet, etomidate has adverse effects, too, which until the current trial were considered possibilities as conflicting evidence suggested significant effect on cortisol and aldosterone levels and potential lung effect with increased risk of pneumonia based on single-dose administration.
Johanning JM. Expanding Options for Total Intravenous Anesthesia—The Etomidate vs Propofol for In-Hospital Complications Trial. JAMA Surg. 2022;157(10):896. doi:10.1001/jamasurg.2022.3339
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.